Anavex Life Sciences News

Calendar of U.S. Earnings Expected in the Week Ahead

Dow JonesNov 22 06:00 ET

Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More

Seeking AlphaNov 18 00:09 ET

Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near?

Simply Wall StNov 6 08:08 ET

Express News | HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target

BenzingaNov 4 06:29 ET

Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion

TipRanksNov 4 06:15 ET · Ratings

Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.

BenzingaOct 31 14:58 ET

12 Health Care Stocks Moving In Thursday's Intraday Session

BenzingaOct 31 12:34 ET

JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsOct 31 11:32 ET · Ratings

Anavex Life Sciences Is Maintained at Buy by EF Hutton

Dow JonesOct 31 09:13 ET · Ratings

Anavex Gains as Lead Asset Slows Alzheimer's Disease Progression by a Third

Seeking AlphaOct 31 06:27 ET

Anavex Reports Phase III Results for Alzheimer's Drug Targeting SIGMAR1 Gene

BenzingaOct 31 04:05 ET

Express News | Anavex Life Sciences Corp - Regulatory Submission of Blarcamesine in Europe Expected This Quarter

ReutersOct 31 04:00 ET

Express News | Anavex Life Sciences Corp - Blarcamesine Slows Clinical Progression by 36.3% Over 48 Weeks

ReutersOct 31 04:00 ET

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024

GlobeNewswireOct 31 04:00 ET

Express News | Anavex’s Blarcamesine Achieves Pre-Specified Efficacy in Phase Iib/III Alzheimer’s Trial: Data Presented at Ctad Conference 2024

ReutersOct 31 04:00 ET

Anavex Life Sciences Analyst Ratings

BenzingaOct 18 07:02 ET · Ratings

H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsOct 18 06:37 ET · Ratings

Buy Rating Affirmed for Anavex Life Sciences Amid Promising Clinical Developments and Market Prospects

TipRanksOct 18 06:25 ET · Ratings

Express News | Anavex Life Sciences Corp - Data From Part B Expected in First Half of 2025

ReutersOct 17 07:31 ET

Express News | Anavex Life Sciences Corp - Anavex(®)3-71 Well Tolerated, No Serious Adverse Events

ReutersOct 17 07:30 ET